Blinded by the light: why the treatment of metastatic melanoma has created a new paradigm for the management of cancer

Therapeutic Advances in Medical Oncology
Colin R LindsayAshita Waterston

Abstract

Until recently, treatment for metastatic melanoma was characterised by a limited availability of treatment options that offer objective survival benefit. Cytotoxic agents fundamentally lack the ability to achieve disease control and cytokine therapy with interleukin-2 has an unacceptably high - for the use across all patient cohorts - rate of toxicities. The validation of braf as an oncogene driving melanoma tumorigenesis, as well as the discovery of the role of CTLA-4 receptor in the evasion of anticancer immune response by melanoma, has revolutionised our treatment options against a disease with dismal prognosis. Quick implementation of translational discoveries brought about BRAF/MEK inhibition in clinic, while at the same time, wider experience with CTLA-4 blockade enabled clinicians to manage previously fatal immune-related toxicities with greater confidence. The suitability for clinical use of other oncogenic drivers such as NRAS and c-kit is currently being tested whilst the PD-1/PD-L1/PD-L2 axis has emerged as a new immunotherapy target with exciting early phase results. The recent exponential progress in treatment of melanoma has set an example of translational medicine and the current review aims to explain why, as we...Continue Reading

References

Feb 1, 1997·Pigment Cell Research·R E Boissy, J J Nordlund
Nov 24, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M B AtkinsS A Rosenberg
Sep 12, 2000·The American Journal of Pathology·B C BastianD Pinkel
Feb 27, 2001·Nature Immunology·Y LatchmanG J Freeman
Jun 18, 2002·Nature·Helen DaviesP Andrew Futreal
Aug 16, 2002·The New England Journal of Medicine·George D DemetriHeikki Joensuu
Aug 29, 2002·Nature·Harith RajagopalanVictor E Velculescu
Mar 15, 2003·The New England Journal of Medicine·Stephen G O'BrienUNKNOWN IRIS Investigators
Jun 6, 2003·Oncogene·María S Soengas, Scott W Lowe
Apr 23, 2005·British Journal of Cancer·S UgurelD Schadendorf
Jun 29, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Robert J Temple
Jul 15, 2005·The New England Journal of Medicine·Frances A ShepherdUNKNOWN National Cancer Institute of Canada Clinical Trials Group
Sep 24, 2005·BMJ : British Medical Journal·Esther de Vries, Jan-Willem W Coebergh
Jan 13, 2006·Dermatologic Therapy·Ahmad A Tarhini, Sanjiv S Agarwala
Jan 19, 2006·The Journal of Investigative Dermatology·Vikas K GoelFrank G Haluska
Aug 2, 2006·British Journal of Cancer·T EisenM J Ratain
Aug 16, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·John A CurtinBoris C Bastian
Feb 23, 2007·Nature·Vanessa Gray-SchopferRichard Marais
May 1, 2008·Pigment Cell & Melanoma Research·Flavia Carneiro Brito, Lidia Kos
May 13, 2008·Expert Review of Anticancer Therapy·Robert R McWilliamsPaul D Brown
Aug 30, 2008·British Journal of Cancer·K B KimV G Prieto
Dec 17, 2008·Nature·Catherine D Van RaamsdonkBoris C Bastian
Mar 24, 2009·Lancet·Ronald P DematteoUNKNOWN American College of Surgeons Oncology Group (ACOSOG) Intergroup Adjuvant GIST Study Team
Apr 7, 2009·Cancer Cell·Nathalie DhomenRichard Marais
Nov 3, 2009·Clinics in Dermatology·Lucia B JilaveanuHarriet M Kluger
Nov 17, 2009·Proceedings of the National Academy of Sciences of the United States of America·Caroline M EmeryLevi A Garraway
Nov 18, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Charles M BalchVernon K Sondak
Jun 8, 2010·The New England Journal of Medicine·F Stephen HodiWalter J Urba
Jul 22, 2010·Cancer Research·Yongping Shao, Andrew E Aplin
Sep 8, 2010·The New England Journal of Medicine·Keith T FlahertyPaul B Chapman
Sep 21, 2010·Pigment Cell & Melanoma Research·Tamara TerzianNeil F Box
Nov 19, 2010·The New England Journal of Medicine·Catherine D Van RaamsdonkBoris C Bastian
Nov 26, 2010·Nature·Cory M JohannessenLevi A Garraway
Jan 6, 2011·PloS One·Patrick A OttAnna C Pavlick

❮ Previous
Next ❯

Methods Mentioned

BETA
dissect
GTPase

Clinical Trials Mentioned

NCT01584648
NCT01721772

Software Mentioned

COMBI

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

Clinical Medicine Insights. Oncology
Charlotte Lemech, Hendrik-Tobias Arkenau
British Journal of Cancer
Keiran Sm Smalley, Keith T Flaherty
The Mount Sinai Journal of Medicine, New York
P A Paciucci
© 2022 Meta ULC. All rights reserved